{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:50:32Z","timestamp":1790704232314,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03398148"],"award-info":[{"award-number":["NCT03398148"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03398135"],"award-info":[{"award-number":["NCT03398135"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>This post hoc analysis evaluated the corticosteroid-sparing effects of risankizumab (RZB) therapy in patients with moderate-to-severe ulcerative colitis in the phase 3 induction and maintenance studies, INSPIRE and COMMAND.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized (2:1) to 12 weeks of intravenous RZB or placebo (PBO) induction therapy; responders to intravenous RZB were randomized (1:1:1) to receive subcutaneous RZB 180\u00a0mg, 360\u00a0mg, or PBO (RZB withdrawal) maintenance therapy. Baseline corticosteroid doses were maintained during induction, with a mandatory taper beginning at maintenance week 0. Efficacy outcomes were evaluated by baseline corticosteroid use at induction week 12, while corticosteroid-free clinical and endoscopic outcomes were assessed at maintenance week 52 among the overall population and among patients on corticosteroids at baseline. Safety was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 35.7% (348\/975) of patients were taking corticosteroids. At induction week 12, greater rates were observed for clinical, endoscopic, and patient-reported outcomes in RZB 1200 mg-treated patients compared with PBO, regardless of baseline corticosteroid use. RZB 180\u00a0mg and 360\u00a0mg treatment resulted in higher corticosteroid discontinuation rates (RZB 180\u00a0mg 64.9% [48\/74]; RZB 360\u00a0mg 54.2% [32\/59]; PBO [withdrawal] 36.8% [25\/68], P\u2005\u2264\u2005.01) and corticosteroid-free clinical, endoscopic, and patient-reported outcomes at week 52, compared with PBO (withdrawal). The rates of treatment-emergent adverse events were similar regardless of baseline corticosteroid use during induction and maintenance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The efficacy of RZB induction therapy was independent of corticosteroid use, with high rates of corticosteroid-free outcomes observed in the overall population and among patients with baseline corticosteroid use, reaffirming the potential of RZB to serve as a corticosteroid-sparing therapy for patients with ulcerative colitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinicaltrial.gov numbers<\/jats:title>\n                    <jats:p>NCT03398148 and NCT03398135<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf025","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T12:56:42Z","timestamp":1743512202000},"source":"Crossref","is-referenced-by-count":4,"title":["Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"first","affiliation":[{"name":"Clinical Department of Gastroenterology and Hepatology, Medical University Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-6851","authenticated-orcid":false,"suffix":"Jr.","given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department Internal Medicine, University Hospital Schleswig-Holstein, Christian-Albrecht University of Kiel , Kiel,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, The University of Chicago Medicine Chicago , Chicago, IL","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology and Digestive Oncology Department, University Hospital CHU of Li\u00e8ge , Li\u00e8ge,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Hecht","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Marced","family":"Barrachina","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Kalabic","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH & Co. KG , Ludwigshafen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Vladea","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Sharma","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijiang Rachel","family":"Duan","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Zhang","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary , Calgary, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2026071701364599800_CIT0001","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ecco-jcc\/jjv218","article-title":"Self-reported symptom burden in individuals with inflammatory bowel disease","volume":"10","author":"Farrell","year":"2016","journal-title":"J Crohns Colitis."},{"key":"2026071701364599800_CIT0002","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med."},{"key":"2026071701364599800_CIT0003","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.gastha.2022.07.003","article-title":"Poor patient-reported outcomes and impaired work productivity in patients with inflammatory bowel disease in remission","volume":"1","author":"Cross","year":"2022","journal-title":"Gastro Hep Adv."},{"key":"2026071701364599800_CIT0004","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s10620-024-08313-z","article-title":"Effect of suboptimal disease control on patient quality of life: real-world data from the observational IBD-PODCAST Canada trial","volume":"69","author":"Siffledeen","year":"2024","journal-title":"Dig Dis Sci."},{"key":"2026071701364599800_CIT0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2026071701364599800_CIT0006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology."},{"key":"2026071701364599800_CIT0007","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/MIB.0000000000001261","article-title":"Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis","volume":"23","author":"Cross","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2026071701364599800_CIT0008","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The historical role and contemporary use of corticosteroids in inflammatory bowel disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2026071701364599800_CIT0009","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/apt.13803","article-title":"Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis","volume":"44","author":"D\u2019Haens","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"2026071701364599800_CIT0010","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s10620-019-05959-y","article-title":"Corticosteroid treatment at diagnosis: an analysis of relapses, disease extension, and colectomy rate in ulcerative colitis","volume":"65","author":"Bertani","year":"2020","journal-title":"Dig Dis Sci."},{"key":"2026071701364599800_CIT0011","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/apt.14334","article-title":"A multicentre audit of excess steroid use in 1176 patients with inflammatory bowel disease","volume":"46","author":"Selinger","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"2026071701364599800_CIT0012","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2036.2008.03753.x","article-title":"Treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease","volume":"28","author":"Panaccione","year":"2008","journal-title":"Aliment Pharmacol Ther."},{"key":"2026071701364599800_CIT0013","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"2026071701364599800_CIT0014","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2026071701364599800_CIT0015","author":"AbbVie","year":"2024"},{"key":"2026071701364599800_CIT0016","author":"AbbVie","year":"2024"},{"key":"2026071701364599800_CIT0017","author":"AbbVie","year":"2024"},{"key":"2026071701364599800_CIT0018","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA."},{"key":"2026071701364599800_CIT0019","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s41669-023-00419-w","article-title":"Content validity and psychometric evaluation of the functional assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in patients with Crohn\u2019s disease and ulcerative colitis","volume":"7","author":"Loftus","year":"2023","journal-title":"PharmacoEcon Open."},{"key":"2026071701364599800_CIT0020","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"2026071701364599800_CIT0021","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"2026071701364599800_CIT0022","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"key":"2026071701364599800_CIT0023","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(24)02315-1","article-title":"Su1751 achievement of corticosteroid-free clinical, endoscopic, and histologic outcomes in patients with moderately to severely active ulcerative colitis treated with risankizumab: results from the COMMAND Study [Abstract]","volume":"166","author":"Loftus","year":"2024","journal-title":"Gastroenterology."},{"key":"2026071701364599800_CIT0024","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"2026071701364599800_CIT0025","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med."},{"key":"2026071701364599800_CIT0026","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"key":"2026071701364599800_CIT0027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/CEG.S248597","article-title":"Sustained corticosteroid-free clinical remission during vedolizumab maintenance therapy in patients with ulcerative colitis on stable concomitant corticosteroids during induction therapy: a post hoc analysis of GEMINI 1","volume":"13","author":"Loftus","year":"2020","journal-title":"Clin Exp Gastroenterol"},{"key":"2026071701364599800_CIT0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12876-021-01604-z","article-title":"Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study","volume":"21","author":"M\u00fchl","year":"2021","journal-title":"BMC Gastroenterol."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf025\/62831144\/jjaf025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/4\/jjaf025\/62831144\/jjaf025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/4\/jjaf025\/62831144\/jjaf025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:36:58Z","timestamp":1784266618000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf025\/8102792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf025","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,4,1]]},"article-number":"jjaf025"}}